Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX Account Payables
Amounts the company owes suppliers for goods and services received.
Forte Biosciences, Inc.NASDAQ: FBRX
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 160.5% from a year ago
Account payables stood at $13.08M at the end of Q1 FY2026, up 160.5% from a year earlier and up 31.0% from the prior quarter. Over 3 fiscal years it compounded at +105.4% a year.
Context
- Account payables amounted to 19.5% of total assets at the end of Q1 FY2026, up 8.9 pp from a year earlier.
- Account payables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +160.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 9.99M USD
- Year-over-year change
- +104.7%
- 4-year CAGR
- +80.3%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.99M | +104.7% |
| FY2024 | 2024-12-31 | 4.88M | +242.6% |
| FY2023 | 2023-12-31 | 1.42M | +23.5% |
| FY2022 | 2022-12-31 | 1.15M | +21.9% |
| FY2021 | 2021-12-31 | 946K | — |
Account Payables vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +160.5% is the highest of 10, against a peer median of -38.8%.
- Account payables amounts to 19.5% of total assets for FBRX, versus a peer median of 1.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $13.08M USD | +160.5% | +105.4% | 19.5% | |
| Mar 2026 | $5.48M USD | +51.0% | +60.5% | 11.1% | |
| Mar 2026 | $3.28M USD | -21.8% | -31.5% | 1.2% | |
| Mar 2026 | CHF 1.92M CHF | -19.9% | -2.0% | 2.2% | |
| Mar 2026 | $1.59M USD | +6.4% | +5.9% | 0.4% | |
| Mar 2026 | $1.42M USD | -38.8% | -26.1% | 0.6% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $1.2M USD | -54.6% | -10.6% | 13.5% |
| Mar 2026 | $622K USD | -77.0% | -15.5% | 0.4% | |
| Mar 2026 | $435K USD | -89.3% | +0.6% | 0.3% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $272K USD | -93.3% | -37.9% | 1.2% |
| Peer median (excluding FBRX) | — | -38.8% | -10.6% | 1.2% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.